Is this you? Create Your Porfile
Avatar

Teru Hideshima

VA Boston Healthcare System

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Teru Hideshima is active.

Explore More

Publication

Featured researches published by Teru Hideshima.

Blood | 2006

Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.

Paul G. Richardson; Sundar Jagannath; David Avigan; Melissa Alsina; R. Schlossman; Amitabha Mazumder; Nc Munshi; Im Ghobrial; Deborah Doss; Mary McKenney; M.G. Farrell; Diane Warren; Laura E. Lunde; B. Gourley; S. Vaccaro; Carol Delaney; S. Pountney; Constantine S. Mitsiades; Teru Hideshima; Catriona Byrne; Robert Knight; Ann Birner; T. Myers; Edie Weller; Kenneth C. Anderson

Blood | 2007

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

Paul G. Richardson; S. Lonial; A. Jakubowiak; Amrita Krishnan; Jeffrey L. Wolf; John J. Densmore; Seema Singhal; Im Ghobrial; J. Stephenson; Jayesh Mehta; Kathleen Colson; Dixil Francis; Tara Kendall; N. Obadike; K. Sullivan; Joel Martin; Teru Hideshima; L. Lai; Peter Sportelli; L. Gardner; Robert Birch; I.C. Henderson; Kenneth C. Anderson

Blood | 2005

A Phase 1 Trial of Lenalidomide (REVLIMID ® ) with Bortezomib (VELCADE ® ) in Relapsed and Refractory Multiple Myeloma.

Paul G. Richardson; R. Schlossman; Nc Munshi; David Avigan; Sundar Jagannath; Melissa Alsina; Deborah Doss; Mary McKenney; Karen Hande; M.G. Farrell; Svetlana Gorelik; Kathleen Colson; Diane Warren; Laura E. Lunde; R. Michelle; G. Cole; Constantine S. Mitsiades; Teru Hideshima; T. Myers; Robert Knight; Kenneth C. Anderson

Archive | 2003

Plasma Cell Tumors

Noopur Raje; Teru Hideshima; Kenneth C. Anderson

Blood | 2007

A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.

Andrzej J. Jakubowiak; Todd M. Zimmerman; Melissa Alsina; Paul G. Richardson; Jonathan L. Kaufman; Tara Kendall; C. Brozo; A. McAllister; C. Leister; Teru Hideshima; Peter Sportelli; L. Gardner; Robert Birch; I.C. Henderson; Kathy Giusti; Kenneth C. Anderson

Blood | 2006

A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).

Paul G. Richardson; S. Lonial; A. Jakubowiak; Jeffrey L. Wolf; Amrita Krishnan; John J. Densmore; Seema Singhal; Im Ghobrial; L. Schwartzberg; Kathleen Colson; J. Harris; T. Kendall; B. Martineau; N. Obadike; K. Sullivan; S. Pearson; Teru Hideshima; L. Lai; Peter Sportelli; L. Gardner; Robert Birch; I.C. Henderson; Kenneth C. Anderson

Blood | 2007

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

Paul G. Richardson; A. Jakubowiak; Jeffrey L. Wolf; Jeffrey P. Allerton; Jeffrey A. Zonder; S. Lonial; Amrita Krishnan; John J. Densmore; Im Ghobrial; Kathleen Colson; T. Kendall; C. Leister; B. Martineau; Teru Hideshima; Thierry Facon; Peter Sportelli; L. Gardner; Robert Birch; I.C. Henderson; Kenneth C. Anderson

Blood | 2002

LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo.

L Catley; Ellen Weisberg; Yt Tai; Boris Lin; Nicholas Mitsiades; Teru Hideshima; Richard LeBlanc; R Shringapure; Renate Burger; Constantine S. Mitsiades; D Chauhan; R. Schlossman; Nikhil C. Munshi; Paul G. Richardson; James D. Griffin; Kenneth C. Anderson

Blood | 2003

Targeting mitochondria to overcome conventional and Bortezomib-resistance in multiple myeloma cells.

D Chauhan; Guilan Li; Klaus Podar; Teru Hideshima; M Nicholas; M Constatntine; L Catley; Nc Munshi; Kenneth C. Anderson

Blood | 2002

Heat shock protein-27 confers drug-resistance in multiple myeloma cells.

D Chauhan; Guilan Li; Teru Hideshima; Klaus Podar; L Catley; Richard LeBlanc; Nicholas Mitsiades; Constantine S. Mitsiades; Paul G. Richardson; S Saxena; Kenneth C. Anderson

Explore More

Collaboration

Dive into the Teru Hideshima's collaboration.

Top Co-Authors
Avatar

Kenneth C. Anderson

Harvard University

View shared research outputs
Top Co-Authors
Avatar

Paul G. Richardson

Harvard University

View shared research outputs
Top Co-Authors
Avatar

Klaus Podar

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors
Avatar

Constantine S. Mitsiades

Harvard University

View shared research outputs
Top Co-Authors
Avatar

Dharminder Chauhan

Northwestern University

View shared research outputs
Top Co-Authors
Avatar

Nikhil C. Munshi

Harvard University

View shared research outputs
Top Co-Authors
Avatar

D Chauhan

Harvard University

View shared research outputs
Top Co-Authors
Avatar

Nc Munshi

Harvard University

View shared research outputs
Top Co-Authors
Avatar

Noopur Raje

Jikei University School of Medicine

View shared research outputs
Top Co-Authors
Avatar

Nicholas Mitsiades

Baylor College of Medicine

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge